• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Idelalisib-related pneumonitis.

作者信息

Haustraete Eglantine, Obert Julie, Diab Samia, Abbes Sarah, Zini Jean-Marc, Valade Sandrine, Lerolle Nathalie, Albin Nicolas, Arnulf Bertrand, Bouaziz Jean-David, Hussenet Claire, Tazi Abdellatif, Bergeron Anne

机构信息

AP-HP, Hôpital Saint-Louis, Service de Pneumologie, Paris, France.

Groupe Médical Mounier, Pneumologie, Grenoble, France.

出版信息

Eur Respir J. 2016 Apr;47(4):1280-3. doi: 10.1183/13993003.01670-2015. Epub 2016 Feb 25.

DOI:10.1183/13993003.01670-2015
PMID:26917607
Abstract
摘要

相似文献

1
Idelalisib-related pneumonitis.依地利斯布相关肺炎
Eur Respir J. 2016 Apr;47(4):1280-3. doi: 10.1183/13993003.01670-2015. Epub 2016 Feb 25.
2
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.随机、III 期研究的最终结果：利妥昔单抗联合或不联合idelalisib 随后开放标签idelalisib 治疗复发慢性淋巴细胞白血病患者。
J Clin Oncol. 2019 Jun 1;37(16):1391-1402. doi: 10.1200/JCO.18.01460. Epub 2019 Apr 17.
3
Disseminated Lomentospora prolificans infection in a patient on idelalisib-rituximab therapy for relapsed chronic lymphocytic leukaemia.一名接受idelalisib-利妥昔单抗治疗复发性慢性淋巴细胞白血病的患者发生播散性多育毛孢子菌感染。
Ann Hematol. 2020 Oct;99(10):2455-2456. doi: 10.1007/s00277-020-04087-2. Epub 2020 May 25.
4
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.idelalisib与entospletinib的2期研究：肺炎限制了复发难治性慢性淋巴细胞白血病和非霍奇金淋巴瘤的联合治疗。
Blood. 2016 May 19;127(20):2411-5. doi: 10.1182/blood-2015-12-683516. Epub 2016 Mar 11.
5
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.一项关于idelalisib联合利妥昔单抗用于初治老年慢性淋巴细胞白血病患者的2期研究。
Blood. 2015 Dec 17;126(25):2686-94. doi: 10.1182/blood-2015-03-630947. Epub 2015 Oct 15.
6
Idelalisib for treatment of B-cell malignancies.idelalisib用于治疗B细胞恶性肿瘤。
Am J Health Syst Pharm. 2016 Apr 15;73(8):547-55. doi: 10.2146/ajhp150281. Epub 2016 Mar 1.
7
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
Am J Hematol. 2024 Jun;99(6):1192-1195. doi: 10.1002/ajh.27304. Epub 2024 Apr 5.
8
Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.idelalisib：一种用于慢性淋巴细胞白血病的新型PI3Kδ抑制剂。
Ann Pharmacother. 2015 Oct;49(10):1162-70. doi: 10.1177/1060028015594813. Epub 2015 Jul 16.
9
A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel).一项回顾性观察研究，评估英国和爱尔兰使用idelalisib 和利妥昔单抗治疗慢性淋巴细胞白血病患者的临床结局和常规管理（RETRO-idel）。
Br J Haematol. 2021 Jul;194(1):69-77. doi: 10.1111/bjh.17475. Epub 2021 Jun 14.
10
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.依鲁替尼联合利妥昔单抗治疗复发慢性淋巴细胞白血病。
N Engl J Med. 2014 Mar 13;370(11):997-1007. doi: 10.1056/NEJMoa1315226. Epub 2014 Jan 22.

引用本文的文献

1
High-flow nasal cannula oxygen therapy versus conventional oxygen therapy in patients undergoing bronchoscopy: a retrospective study.支气管镜检查患者高流量鼻导管给氧疗法与传统氧疗的比较：一项回顾性研究
BMC Pulm Med. 2024 Dec 18;24(1):614. doi: 10.1186/s12890-024-03440-9.
2
Updates in Drug-Related Pneumonitis Due to Targeted Oncologic Therapies.靶向肿瘤治疗所致药物相关性肺炎的进展
J Immunother Precis Oncol. 2024 Nov 1;7(4):272-282. doi: 10.36401/JIPO-24-12. eCollection 2024 Nov.
3
Development and safety of PI3K inhibitors in cancer.
PI3K 抑制剂在癌症中的研发与安全性。
Arch Toxicol. 2023 Mar;97(3):635-650. doi: 10.1007/s00204-023-03440-4. Epub 2023 Feb 11.
4
An unusual case of Idelalisib-related pneumonitis with severe respiratory failure.一例罕见的与idelalisib相关的肺炎伴严重呼吸衰竭病例。
EJHaem. 2020 Oct 26;1(2):420-421. doi: 10.1002/jha2.123. eCollection 2020 Nov.
5
Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.管理磷脂酰肌醇-3-激酶（PI3K）抑制剂的毒性。
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):346-356. doi: 10.1182/hematology.2020000119.
6
Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.肿瘤治疗中磷脂酰肌醇-3-激酶（PI3K）抑制剂的安全性和耐受性
Drug Saf. 2019 Feb;42(2):247-262. doi: 10.1007/s40264-018-0778-4.
7
Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.伊德拉利昔单抗治疗慢性淋巴细胞白血病和滤泡性淋巴瘤相关不良事件的管理：多学科立场文件。
Hematol Oncol. 2019 Feb;37(1):3-14. doi: 10.1002/hon.2540. Epub 2018 Sep 5.
8
Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation.慢性淋巴细胞白血病的靶向治疗综述：放射科医生需要了解 CT 解读的知识。
Cancer Imaging. 2018 Apr 18;18(1):13. doi: 10.1186/s40644-018-0146-8.
9
Incidence, clinical characteristics, and outcome of interstitial pneumonia in patients with lymphoma.淋巴瘤患者间质性肺炎的发病率、临床特征及预后
Ann Hematol. 2018 Jan;97(1):133-139. doi: 10.1007/s00277-017-3157-9. Epub 2017 Oct 31.
10
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.伊布替尼和idelalisib 相关毒性的发生率和处理：实用方法。
Haematologica. 2017 Oct;102(10):1629-1639. doi: 10.3324/haematol.2017.164103. Epub 2017 Aug 3.